ArticleCancers2022

Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer.

Chan Su Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.